Hims & Hers Health shares drop almost 5% after analyst rating shifts to 'hold' despite technical support

Traders Union
All News
Financial News
Hims & hers slides 4.82% today

Highlights

Zacks Research upgraded Hims & Hers Health Inc from 'strong sell' to 'hold', reflecting a neutral shift in analyst sentiment.
No new forecasts or major company-specific events accompanied the rating change, and shares remain under broad selling pressure.
Technicals indicate short-term uptrend with support at $35.19 and expected range of $33.31 to $37.45, but overbought conditions and downside gap signal caution.

Rating boost spurs sentiment shift amid continued selling flows

Zacks Research upgraded Hims & Hers Health Inc from a 'strong sell' to a 'hold' rating in its latest report. The change was specific to the company's standing and did not introduce forecasts or speculative details. No additional significant corporate actions or regulatory events were reported, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees the recent Hims & Hers Health decline as a warning sign despite some technical support. He notes that the rating upgrade to 'hold' does little to offset ongoing selling pressure and overbought signals. The bearish long-term moving average alignment concerns him, especially with momentum indicators sending mixed messages and the Awesome Oscillator failing to confirm strength. Kharitonov highlights the downside risk if support at $35.19 fails, with a potential move below $33.31 increasing vulnerability. "Recent upgrades are not enough — unless buyers defend support, a deeper correction could be on the horizon."

Viktoras Karapetjanc, expert at Traders Union, views the Zacks Research upgrade as a stabilizing factor for Hims & Hers Health. He believes strong technical structure across all major averages sets a bullish tone. With momentum and sentiment indicators still counting 19 buys, further growth is expected if the price breaks above $37.45. Karapetjanc maintains that the outlook remains constructive, as the market offers multiple setups for continuation. "The bullish structure remains intact — I see this as a base for the next leg higher toward new highs."

Strong momentum faces caution as bearish alignment emerges

Hims & Hers Health is trading above its 20-day, 50-day, and 200-day moving averages ($34.71, $29.58, and $31.91 respectively), underscoring strength across short-, medium-, and long-term timeframes. Currently, the stock is positioned just above support at $35.19, with resistance at the recent week high of $37.43. The MA-50 versus MA-200 structure signals a bearish alignment, suggesting some caution for the longer-term trend even as the uptrend persists. Momentum indicators provide mixed readings: MACD and ADX both signal a strong buy, and the RSI is elevated at 63.29 with a 'Buy' signal. The CCI backs a 'Buy', but the Stochastic RSI is near neutral. Bull/Bear Power stands positive at 2.32 but is flagged as overbought, while the Awesome Oscillator fails to confirm the current uptrend. HIMS recently declined $1.79 or 4.82%, opening with a downside gap of roughly 1.37% and sitting near the session low. Intraday volatility is measured at 6.85%, and the price action is currently pressured toward support zones after a period of strong technical momentum.

Earlier, analysts noted that Hims & Hers Health exhibited persistent bullish momentum but cautioned that growing overbought risks and bearish technical alignments warranted vigilance. The latest developments reinforce the need for active monitoring, as heightened volatility and recent analyst rating changes increase the likelihood of sharp moves should current support or resistance levels be breached.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.